Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 10/2019

01-10-2019 | Obesity | Original Article

Placental expressions and serum levels of adiponectin, visfatin, and omentin in GDM

Authors: Xaynaly Souvannavong-Vilivong, Chantacha Sitticharoon, Roongrit Klinjampa, Issarawan Keadkraichaiwat, Chanakarn Sripong, Saimai Chatree, Rungnapa Sririwichitchai, Tripop Lertbunnaphong

Published in: Acta Diabetologica | Issue 10/2019

Login to get access

Abstract

Aims

Adiponectin, visfatin, and omentin have been shown to be associated with insulin sensitivity and might have a role in the pathophysiology of gestational diabetes mellitus (GDM). This study aimed to (1) compare adiponectin, visfatin, and omentin mRNA expressions in placenta and their serum levels between normal pregnancy (NP) and GDM class A1 (GDMA1) pregnancy and (2) determine correlations between placental gene expressions as well as serum levels with maternal and neonatal clinical parameters in all, NP, and GDM subjects.

Methods

NP subjects (n = 37), who had normal medical history during their pregnancies without diagnosis of any abnormalities and GDMA1 subjects (n = 37), who were diagnosed since they had antenatal care, were recruited when they were in labor with a gestational age of at least 34 weeks. Clinical parameters and serum adiponectin, visfatin, and omentin levels were measured in the delivery room.

Results

GDMA1 subjects had higher serum visfatin and plasma glucose levels, but lower serum omentin levels (p  < 0.05 all) compared to controls, with comparable levels of placental adiponectin, visfatin, and omentin expressions, plasma insulin, and indices of insulin sensitivity and insulin resistance. Serum visfatin was negatively correlated with neonatal weight and length in the GDM group (p  < 0.05 all). Serum omentin was negatively correlated with pre-pregnancy body mass index and waist circumference only in the NP group (p  < 0.05 all). Serum adiponectin was negatively correlated with maternal age and HOMA-IR in the NP group (p  < 0.05 all) and with placental weight and serum omentin in the GDM group (p  < 0.05 all).

Conclusions

In conclusion, in GDMA1, increased serum visfatin, which has insulin-mimetic effect, might be associated with a compensatory mechanism that improves the impaired insulin function. Decreased serum omentin in GDMA1, which is normally found in visceral obesity, might lead to insulin resistance and contribute to the pathophysiology of GDM.
Literature
1.
2.
De Souza LR, Berger H, Retnakaran R et al (2016) First-trimester maternal abdominal adiposity predicts dysglycemia and gestational diabetes mellitus in midpregnancy. Diabetes Care 39(1):61–64CrossRefPubMed
3.
4.
Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270(45):26746–26749CrossRefPubMed
5.
Chen J, Tan B, Karteris E et al (2006) Secretion of adiponectin by human placenta: differential modulation of adiponectin and its receptors by cytokines. Diabetologia 49(6):1292–1302CrossRefPubMed
6.
Yamauchi T, Kamon J, Waki H et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7(8):941–946CrossRefPubMed
7.
Sitticharoon C, Nway NC, Chatree S, Churintaraphan M, Boonpuan P, Maikaew P (2014) Interactions between adiponectin, visfatin, and omentin in subcutaneous and visceral adipose tissues and serum, and correlations with clinical and peripheral metabolic factors. Peptides 62:164–175CrossRefPubMed
8.
9.
Weyer C, Funahashi T, Tanaka S et al (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86(5):1930–1935CrossRefPubMed
10.
Park KG, Park KS, Kim MJ et al (2004) Relationship between serum adiponectin and leptin concentrations and body fat distribution. Diabetes Res Clin Pract 63(2):135–142CrossRefPubMed
11.
Catalano PM, Hoegh M, Minium J et al (2006) Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism. Diabetologia 49(7):1677–1685 Epub 2006 May 11 CrossRefPubMed
12.
Lowe LP, Metzger BE, Lowe WL Jr, Dyer AR, McDade TW, McIntyre HD (2010) Inflammatory mediators and glucose in pregnancy: results from a subset of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. J Clin Endocrinol Metab 95(12):5427–5434CrossRefPubMedPubMedCentral
13.
Matuszek B, Burska A, Leszczynska-Gorzelak B, Donica H, Nowakowski A (2013) Comparative analysis of adiponectin isoform distribution in pregnant women with gestational diabetes mellitus and after delivery. Acta Obstet Gynecol Scand 92(8):951–959CrossRefPubMed
14.
Xu J, Zhao YH, Chen YP et al (2014) Maternal circulating concentrations of tumor necrosis factor-alpha, leptin, and adiponectin in gestational diabetes mellitus: a systematic review and meta-analysis. Sci World J 2014:926932
15.
16.
Adeghate E (2008) Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem 15(18):1851–1862CrossRefPubMed
17.
18.
Chan TF, Chen YL, Lee CH et al (2006) Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Investig 13(5):364–367CrossRefPubMed
19.
Fukuhara A, Matsuda M, Nishizawa M et al (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708):426–430 Epub 2004 Dec 16 CrossRefPubMed
20.
Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M et al (2006) Serum visfatin increases with progressive beta-cell deterioration. Diabetes 55(10):2871–2875CrossRefPubMed
21.
22.
Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J et al (2007) Serum concentration of visfatin in obese women. Metabolism. 56(8):1131–1134CrossRefPubMed
23.
Sitticharoon C, Nway NC, Chatree S, Churintaraphan M, Boonpuan P, Maikaew P (2014) Interactions between adiponectin, visfatin, and omentin in subcutaneous and visceral adipose tissues and serum, and correlations with clinical and peripheral metabolic factors. Peptides 62:164–175CrossRefPubMed
24.
Derosa G, Fogari E, D’Angelo A et al (2013) Adipocytokine levels in obese and non-obese subjects: an observational study. Inflammation. 36:914–920CrossRefPubMed
25.
Pagano C, Pilon C, Olivieri M et al (2006) Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91(8):3165–3170CrossRefPubMed
26.
Krzyzanowska K, Krugluger W, Mittermayer F et al (2006) Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond). 110(5):605–609CrossRefPubMed
27.
28.
29.
Tsuji S, Uehori J, Matsumoto M et al (2001) Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem 276(26):23456–23463CrossRefPubMed
30.
31.
Tan BK, Adya R, Farhatullah S et al (2008) Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 57(4):801–808CrossRefPubMed
32.
de Souza Batista CM, Yang RZ, Lee MJ et al (2007) Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56(6):1655–1661 Epub 2007 Feb 28 CrossRefPubMed
33.
Barker G, Lim R, Georgiou HM, Lappas M (2012) Omentin-1 is decreased in maternal plasma, placenta and adipose tissue of women with pre-existing obesity. PLoS ONE 7(8):e42943CrossRefPubMedPubMedCentral
34.
Lewandowski K, Nadel I, Lewinski A et al (2010) Positive correlation between serum omentin and thrombospondin-1 in gestational diabetes despite lack of correlation with insulin resistance indices. Ginekol Pol 81(12):907–912PubMed
35.
Lappas M, Yee K, Permezel M, Rice GE (2005) Release and regulation of leptin, resistin and adiponectin from human placenta, fetal membranes, and maternal adipose tissue and skeletal muscle from normal and gestational diabetes mellitus-complicated pregnancies. J Endocrinol 186(3):457–465CrossRefPubMed
36.
37.
Abell SK, De Courten B, Boyle JA, Teede HJ (2015) Inflammatory and other biomarkers: role in pathophysiology and prediction of gestational diabetes mellitus. Int J Mol Sci 16(6):13442–13473CrossRefPubMedPubMedCentral
38.
Sunsaneevithayakul P, Boriboohirunsarn D, Sutanthavibul A et al (2003) Risk factor-based selective screening program for gestational diabetes mellitus in Siriraj Hospital: result from clinical practice guideline. J Med Assoc Thail 86(8):708–714
39.
Cleal JK, Day P, Hanson MA, Lewis RM (2009) Measurement of housekeeping genes in human placenta. Placenta 30(11):1002–1003CrossRefPubMed
40.
Coskun A, Ozkaya M, Kiran G, Kilinc M, Arikan DC (2010) Plasma visfatin levels in pregnant women with normal glucose tolerance, gestational diabetes and pre-gestational diabetes mellitus. J Matern Fetal Neonatal Med. 23(9):1014–1018CrossRefPubMed
41.
Gabbe SG (1981) Diabetes mellitus in pregnancy: have all the problems been solved? Am J Med 70(3):613–618CrossRefPubMed
42.
Shokry E, Marchioro L, Uhl O et al (2019) Impact of maternal BMI and gestational diabetes mellitus on maternal and cord blood metabolome: results from the PREOBE cohort study. Acta Diabetol 56(4):421–430CrossRefPubMed
43.
Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M (2006) The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 49(8):1909–1914CrossRefPubMed
44.
Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B (2006) Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 91(4):1578–1581CrossRefPubMed
45.
Szamatowicz J, Kuzmicki M, Telejko B et al (2009) Serum visfatin concentration is elevated in pregnant women irrespectively of the presence of gestational diabetes. Ginekol Pol 80(1):14–18PubMed
46.
Akturk M, Altinova AE, Mert I et al (2008) Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester. J Endocrinol Invest 31(7):610–613CrossRefPubMed
47.
Nway NC, Sitticharoon C, Chatree S, Maikaew P (2016) Correlations between the expression of the insulin sensitizing hormones, adiponectin, visfatin, and omentin, and the appetite regulatory hormone, neuropeptide Y and its receptors in subcutaneous and visceral adipose tissues. Obes Res Clin Pract. 10(3):256–263CrossRefPubMed
48.
Bergmann K, Sypniewska G (2013) Diabetes as a complication of adipose tissue dysfunction. Is there a role for potential new biomarkers? Clin Chem Lab Med. 51(1):177–185CrossRefPubMed
49.
Kabir M, Catalano KJ, Ananthnarayan S et al (2005) Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab 288(2):E454–E461CrossRefPubMed
50.
Simons PJ, van den Pangaart PS, Aerts JM, Boon L (2007) Pro-inflammatory delipidizing cytokines reduce adiponectin secretion from human adipocytes without affecting adiponectin oligomerization. J Endocrinol 192(2):289–299CrossRefPubMed
51.
Mohlig M, Wegewitz U, Osterhoff M et al (2002) Insulin decreases human adiponectin plasma levels. Horm Metab Res 34(11–12):655–658CrossRefPubMed
52.
Hivert M-F, Sun Q, Shrader P, Mantzoros CS, Meigs JB, Hu FB (2011) Higher adiponectin levels predict greater weight gain in healthy women in the Nurses’ Health Study. Obesity (Silver Spring, Md). 19(2):409–415CrossRef
53.
Shoelson SE, Herrero L, Naaz A (2007) Obesity, inflammation, and insulin resistance. Gastroenterology 132(6):2169–2180CrossRefPubMed
54.
Simons PJ, van den Pangaart PS, Aerts JM, Boon L (2007) Pro-inflammatory delipidizing cytokines reduce adiponectin secretion from human adipocytes without affecting adiponectin oligomerization. J Endocrinol 192(2):289–299CrossRefPubMed
55.
Zheng J, Xiao X, Zhang Q et al (2014) Correlation of high-molecular-weight adiponectin and leptin concentrations with anthropometric parameters and insulin sensitivity in newborns. Int J Endocrinol 2014:435376PubMedPubMedCentral
Metadata
Title
Placental expressions and serum levels of adiponectin, visfatin, and omentin in GDM
Authors
Xaynaly Souvannavong-Vilivong
Chantacha Sitticharoon
Roongrit Klinjampa
Issarawan Keadkraichaiwat
Chanakarn Sripong
Saimai Chatree
Rungnapa Sririwichitchai
Tripop Lertbunnaphong
Publication date
01-10-2019
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 10/2019
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-019-01355-0

Other articles of this Issue 10/2019

Acta Diabetologica 10/2019 Go to the issue

Short Communication

Plasma apolipoprotein C1 concentration is associated with plasma triglyceride concentration but not with visceral fat and liver fat content in people with type 1 diabetes

Original Article

Can internet search engine queries be used to diagnose diabetes? Analysis of archival search data

Original Article

Pancreatic perfusion and its response to glucose as measured by simultaneous PET/MRI

Review Article

The impact of diabetes mellitus on clinical outcomes following chemotherapy for the patients with pancreatic cancer: a meta-analysis

Original Article

TRActional DIabetic reTInal detachment surgery with co-adjuvant intravitreal dexamethasONe implant: the TRADITION STUDY

Original Article

Temporal trends without seasonal effects on gestational diabetes incidence relate to reductions in indices of insulin secretion: the Cambridge Baby Growth Study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits